CIK 0000715446 · Non-accelerated filer<br>Smaller reporting company
Anixa Biosciences Inc
Sign in to watch- Ticker
- ANIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Oct 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 112622630
- Phone
- 408-708-9808
- Business address
- 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
- Former names
- ITUS Corp, COPYTELE INC
- 4 Open-market buy Director bought 2,000 shares at $5.75 ($11,500)
- SC 13D/A Stake Beneficial Ownership Report
- SC 13D Stake Beneficial Ownership Report
- 4 Open-market buy Director bought 1,500 shares at $5.63 ($8,445)
- 4 Open-market buy Director bought 5,548 shares at $5.71 ($31,679)
- 4 Open-market buy Director bought 7,000 shares at an average $5.47 ($38,300)
- 4 Open-market buy President and CEO bought 5,000 shares at $5.77 ($28,850)
- 4 Open-market buy Director bought 5,000 shares at $5.69 ($28,450)
- 4 Open-market buy Director bought 1,500 shares at $5.99 ($8,985)
- 4 Open-market buy Director bought 2,000 shares at an average $5.41 ($10,820)
- 4 Open-market buy Director bought 4,400 shares at an average $5.46 ($24,034)
- 4 Open-market buy Director bought 9,400 shares at an average $5.46 ($51,320)
- SC 13D Stake Beneficial Ownership Report
- SC 13D Stake Beneficial Ownership Report
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Open-market buy President and CEO bought 200 shares at $4.00 ($800)
- CERTNAS Other Certification by the Nasdaq Stock Market
- 8-K Event Delisting notice
- 8-A12B Other Registration of Securities
Page 24 of 50 · 983 filings